molecules of the month


GSK3β-sparing DYRK1A kinase inhibitor

orally efficacious in proliferation model, but non-specific proliferation observed

from cellular phenotypic screen and opt.

J. Med. Chem. Feb. 20, 2020

Novartis (GNF), San Diego, CA

Structure of selective DYRK1A inhibitor GNF2133
1 min read

GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: